Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $8.1 million.

  • Arcturus Therapeutics Holdings' Gains from Investment Securities fell 88.25% to $564,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $7.6 million, marking a year-over-year decrease of 77.97%. This contributed to the annual value of $8.1 million for FY2024, which is 1.35% up from last year.
  • As of FY2024, Arcturus Therapeutics Holdings' Gains from Investment Securities stood at $8.1 million, which was up 1.35% from $8.0 million recorded in FY2023.
  • In the past 5 years, Arcturus Therapeutics Holdings' Gains from Investment Securities registered a high of $8.1 million during FY2024, and its lowest value of $3.3 million during FY2020.
  • Moreover, its 3-year median value for Gains from Investment Securities was $8.0 million (2023), whereas its average is $7.6 million.
  • Data for Arcturus Therapeutics Holdings' Gains from Investment Securities shows a peak YoY surged of 101.61% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Arcturus Therapeutics Holdings' Gains from Investment Securities stood at $3.3 million in 2020, then spiked by 39.97% to $4.7 million in 2021, then surged by 42.32% to $6.6 million in 2022, then increased by 20.36% to $8.0 million in 2023, then grew by 1.35% to $8.1 million in 2024.